Prot #CDRB436J12301: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV6

Project: Research project

Project Details

StatusActive
Effective start/end date12/20/2212/10/28

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CDRB436J12301)